{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:01:49Z","timestamp":1649206909099},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2008,8,8]],"date-time":"2008-08-08T00:00:00Z","timestamp":1218153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"DOI":"10.1007\/s00393-008-0339-9","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T15:59:28Z","timestamp":1218038368000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnose und Therapie neurologischer Manifestationen bei entz\u00fcndlich-rheumatischen Erkrankungen"],"prefix":"10.1007","author":[{"given":"C.","family":"Dejaco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.K.","family":"Storch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,8]]},"reference":[{"key":"339_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00393-004-0616-1","volume":"63","author":"Neuhaus","year":"2004","unstructured":"Neuhaus O, Hartung H (2004) Neurological aspects of systemic rheumatological disorders. Z Rheumatol 63: 104\u2013112","journal-title":"Z Rheumatol"},{"key":"339_CR2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","volume":"42","author":"Nomenclature","year":"1999","unstructured":"Nomenclature AAHCoNL (1999) The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599\u2013608","journal-title":"Arthritis Rheum"},{"key":"339_CR3","unstructured":"Berlit P, Melms A, Seidel G et al. (2005) Zerebrale Vaskulitis. In: Diener H, Putzki N, Berlit P et al. (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 3. Aufl. Thieme, Stuttgart, S 268\u2013283"},{"key":"339_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00063-003-1230-8","volume":"98","author":"Weiner","year":"2003","unstructured":"Weiner SM, Otte A, Uhl M et al. (2003) Neuropsychiatric involvement in systemic lupus erythematosus. Part 2: diagnostic and therapy. Med Klin 98: 79\u201390","journal-title":"Med Klin"},{"key":"339_CR5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/978-3-7091-6467-9_4","volume":"53","author":"Fazekas","year":"1998","unstructured":"Fazekas F, Schmidt R, Kleinert R et al. (1998) The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates. J Neural Transm 53 (Suppl): S31\u2013S39","journal-title":"J Neural Transm"},{"key":"339_CR6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"Wingerchuk","year":"2007","unstructured":"Wingerchuk D, Lennon V, Lucchinetti C et al. (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6: 805\u2013815","journal-title":"Lancet Neurol"},{"key":"339_CR7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archpsyc.1981.01780290105011","volume":"38","author":"Ling","year":"1981","unstructured":"Ling MH, Perry PJ, Tsuang MT (1981) Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry 38: 471\u2013477","journal-title":"Arch Gen Psychiatry"},{"key":"339_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2004.025528","volume":"64","author":"Barile-Fabris","year":"2005","unstructured":"Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L et al. (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprenisolone in severe neurological manifestations in systemic lupus erythematous. Ann Rheum Dis 64: 620\u2013625","journal-title":"Ann Rheum Dis"},{"key":"339_CR9","first-page":"808","volume":"26","author":"Wang","year":"1999","unstructured":"Wang C, Fortin PR, Li Y et al. (1999) Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 26: 808\u2013815","journal-title":"J Rheumatol"},{"key":"339_CR10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D et al. (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66: 470\u2013475","journal-title":"Ann Rheum Dis"},{"key":"339_CR11","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","volume":"56","author":"Erkan","year":"2007","unstructured":"Erkan D, Harrison MJ, Levy R et al. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56: 2382\u20132391","journal-title":"Arthritis Rheum"},{"key":"339_CR12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman A et al. (1999) Neurological complications in Beh\u00e7et\u2019s syndrome. Brain 122: 2183\u20132194","journal-title":"Brain"},{"key":"339_CR13","doi-asserted-by":"crossref","unstructured":"Hatemi G, Silman A, Bang D et al. (2008) Management of behcet\u2019s disease: a systematic literature review for the EULAR evidence based recommendations for the management of behcet\u2019s disease. Ann Rheum Dis [Epub ahead of print]","DOI":"10.1136\/ard.2008.087957"},{"key":"339_CR14","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B (1999) Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain 122: 2171\u20132182","journal-title":"Brain"},{"key":"339_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"Pipitone","year":"2008","unstructured":"Pipitone N, Olivieri I, Padula A et al. (2008) Infliximab for the treatment of Neuro-Beh\u00e7et\u2019s disease: a case series and review of the literature. Arthritis Rheum 59: 285\u2013290","journal-title":"Arthritis Rheum"},{"key":"339_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00124743-200208000-00002","volume":"8","author":"Anaya","year":"2002","unstructured":"Anaya J, Villa L, Restrepo L et al. (2002) Central nervous system compromise in primary Sj\u00f6gren\u2019s syndrome. J Clin Rheumatol 8: 189\u2013196","journal-title":"J Clin Rheumatol"},{"key":"339_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","volume":"83","author":"Delalande","year":"2004","unstructured":"Delalande S, de Seze J, Fauchais A et al. (2004) Neurologic manifestations in primary Sj\u00f6gren syndrome: a study of 82 patients. Medicine 83: 280\u2013291","journal-title":"Medicine"},{"key":"339_CR18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200115080-00003","volume":"15","author":"Govoni","year":"2001","unstructured":"Govoni M, Padovan M, Rizzo N et al. (2001) CNS involvement in primary Sj\u00f6gren\u2019s syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 15: 597\u2013607","journal-title":"CNS Drugs"},{"key":"339_CR19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/art.23102","volume":"57","author":"Terrier","year":"2007","unstructured":"Terrier B, Lacroix C, Guillevin L et al. (2007) Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sj\u00f6gren\u2019s syndrome-related neuropathy. Arthritis Rheum 57: 1520\u20131529","journal-title":"Arthritis Rheum"},{"key":"339_CR20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0961203307078201","volume":"16","author":"Yamout","year":"2007","unstructured":"Yamout B, El-Hajj T, Barada W et al. (2007) Successful treatment of refractory neuroSjogren with Rituximab. Lupus 16: 521\u2013523","journal-title":"Lupus"},{"key":"339_CR21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s004150170154","volume":"248","author":"Siva","year":"2001","unstructured":"Siva A (2001) Vasculitis of the nervous system. J Neurol 248: 451\u2013468","journal-title":"J Neurol"},{"key":"339_CR22","first-page":"40","volume":"5","author":"Dejaco","year":"2007","unstructured":"Dejaco C, Duftner C, Schirmer M (2007) Therapie der Polymyalgia rheumatica und Riesenzellarteritis. Jatros Orthop\u00e4die 5: 40\u201341","journal-title":"Jatros Orthop\u00e4die"},{"key":"339_CR23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA et al. (1990) The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33: 1122\u20131128","journal-title":"Arthritis Rheum"},{"key":"339_CR24","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF et al. (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56: 2789\u20132797","journal-title":"Arthritis Rheum"},{"key":"339_CR25","doi-asserted-by":"crossref","unstructured":"Berlit P (2004) Cerebral vasculitis Nervenarzt 75: 817\u2013828","DOI":"10.1007\/s00115-004-1750-3"},{"key":"339_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 352: 351\u2013361","journal-title":"N Engl J Med"},{"key":"339_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00393-008-0284-7","volume":"67","author":"Zwerina","year":"2008","unstructured":"Zwerina J (2008) Churg-Strauss syndrome. Z Rheumatol 67: 137\u2013143","journal-title":"Z Rheumatol"},{"key":"339_CR28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1081-1206(10)61714-0","volume":"92","author":"Tsurikisawa","year":"2004","unstructured":"Tsurikisawa N, Taniguchi M, Saito H et al. (2004) Treatment of churg-strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92: 80\u201387","journal-title":"Ann Allergy Asthma Immunol"},{"key":"339_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1474-4422(04)00805-1","volume":"3","author":"Hoitsma","year":"2004","unstructured":"Hoitsma E, Faber C, Drent M et al. (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3: 397\u2013407","journal-title":"Lancet Neurol"},{"key":"339_CR30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s004150170175","volume":"248","author":"Nowak","year":"2001","unstructured":"Nowak DA, Widenka DC (2001) Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 248: 363\u2013372","journal-title":"J Neurol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-008-0339-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0339-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:35:56Z","timestamp":1559061356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-008-0339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,8]]},"references-count":30,"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1007\/s00393-008-0339-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,8]]}}}